The present invention provides an antigen-presenting cell(APC)/tumor cell conjugate, wherein the antigen-presenting cell (APC) is modified by a cytokine gene selected from the group consisting of IL-2, IL-3, IL-4, IL-6, IL-12, IL-18, IFN.alpha., IFN.beta., IFN.gamma., TNF, TGF, GM-CSE, and the combination thereof. The conjugate is useful as a tumor vaccine to significantly induce an immunity specifically against the tumor cell The present invention also provides the method for preparing the conjugate and a pharmaceutical composition containing said conjugate.

 
Web www.patentalert.com

< Matrix metalloproteinase and tumor necrosis factor inhibitors

< 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones which control inflammatory cytokines

> Substituted pyridinones

> Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-.alpha. converting enzyme

~ 00273